← Back to patent-cliff list
BEBT-701
Tier C — Watch / tradeBEBT-701
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：AGT, PCSK9
Indications (approved)：Hypercholesterolaemia, Hypertension, Hyperlipidaemia
Regional status
US
Phase I
2026-04-30
EU
-
China
Phase II
2026-03-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BEBT-701?
Approved indications include: Hypercholesterolaemia, Hypertension, Hyperlipidaemia.
When does the BEBT-701 patent expire?
No public expiry year is available for BEBT-701 yet; this page updates once verified.
How do I get a quote for BEBT-701 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29